Valuation: Lexaria Corp

Market Cap 13.88M 12.13M 11.14M 10.39M 19.69M 1.32B 20.03M 134M 51.98M 648M 52.13M 51M 2.23B P/E 2026 *
-2.15x
P/E 2027 * -1.81x
Enterprise Value 13.88M 12.13M 11.14M 10.39M 19.69M 1.32B 20.03M 134M 51.98M 648M 52.13M 51M 2.23B EV / Sales 2026 *
-
EV / Sales 2027 * 9.9x
Free-Float
94.26%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 57 2024-08-30
Director of Finance/CFO 66 2024-09-30
President 55 2015-04-14
Director TitleAgeSince
Chairman 65 2006-10-25
Director/Board Member 57 2025-01-13
Director/Board Member 72 2011-07-07
Change 5-day change 1-year change 3-year change Capi.($)
+1.86%+7.65%+55.77%+158.84% 1,063B
+3.57%+7.42%+69.09%+58.92% 611B
+3.99%+7.37%+36.87%+93.77% 444B
-1.20%-1.94%+26.41%+20.22% 324B
+4.94%+3.39%+39.92%+28.93% 285B
+2.42%+1.60%+30.06%+42.24% 283B
+2.47%+5.18%-24.80%-39.60% 219B
+3.55%+6.05%+26.04%+68.52% 195B
+4.21%+6.00%+17.72%+70.33% 156B
Average +2.34%+4.27%+30.79%+55.80% 397.85B
Weighted average by Cap. +1.85%+5.08%+41.55%+80.68%

Financials

2026 *2027 *
Net sales - 1.4M 1.23M 1.13M 1.05M 1.99M 134M 2.02M 13.55M 5.25M 65.51M 5.27M 5.15M 226M
Net income -6.4M -5.59M -5.14M -4.79M -9.08M -609M -9.23M -61.84M -23.97M -299M -24.03M -23.51M -1.03B -8.95M -7.82M -7.18M -6.69M -12.69M -852M -12.91M -86.44M -33.5M -418M -33.59M -32.86M -1.44B
Net Debt - -
Logo Lexaria Corp
Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company's patented drug delivery formulation and processing platform technology improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has also evidenced an ability to deliver some drugs effectively across the blood brain barrier. The Company’s segment includes Intellectual Property, B2B Production, and Research and Development. It is advancing several research and development (R&D) activities in both preclinical and clinical programs. Its focus is the investigation and the incorporation of its DehydraTECH drug delivery technology with glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) to enhance absorption and reduce adverse side effects. The Company operates a licensed in-house research laboratory and holds an intellectual property portfolio with around 48 patents granted and many patents pending worldwide.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-